Diagnostic performance of LIVERFASt as a non-invasive liver fibrosis test: data from three cohorts (JGLD manuscript)
Diagnostic performance of LIVERFASt as a non-invasive liver fibrosis test: data from three cohorts (JGLD manuscript)
Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia)
Comparison of prevalence of advanced fibrosis using LiverSTAT or FIB-4 combined with LSM/VCTE in a prospective chronic liver disease cohort (Mongolia)
LIVERSTAT first-line screening tool: MAFLD patients outperformed standard-of-care FIB-4 (training/validation)
LIVERSTAT first-line screening tool: MAFLD patients outperformed standard-of-care FIB-4 (training/validation)
Recommended Clinical Care Pathway with FIB-4 underestimates the prevalence of Advanced Fibrosis, compared to sequential CCP with LIVERSTAT and LSM (NHANES)
Recommended Clinical Care Pathway with FIB-4 underestimates the prevalence of Advanced Fibrosis, compared to sequential CCP with LIVERSTAT and LSM (NHANES)
LIVERFASt-LFS NIT for Fatty Liver Disease, for Primary Care Provider (PCP) screening
LIVERFASt-LFS NIT for Fatty Liver Disease, for Primary Care Provider (PCP) screening
Assessment of Fatty Liver Disease using LIVERFASt in South-East Asia (real-world evidence)
Assessment of Fatty Liver Disease using LIVERFASt in South-East Asia (real-world evidence)
Long-term prognosis of MAFLD patients according to non-invasive methods
Long-term prognosis of MAFLD patients according to non-invasive methods
LIVERFASt Demonstrates the Feasibility of a Screening Program for MASLD
LIVERFASt Demonstrates the Feasibility of a Screening Program for MASLD